25 related articles for article (PubMed ID: 30474304)
1. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer.
Samy MD; Tong WL; Yavorski JM; Sexton WJ; Blanck G
Cancer Immunol Immunother; 2017 Mar; 66(3):403-410. PubMed ID: 27995306
[TBL] [Abstract][Full Text] [Related]
2. An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.
Cheng P; Cios KJ; Varkhedi M; Barker VR; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Oncoscience; 2023; 10():59-66. PubMed ID: 37953875
[TBL] [Abstract][Full Text] [Related]
3. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
[TBL] [Abstract][Full Text] [Related]
4. Tumor resident, TRA anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome.
Diaz MJ; Kacsoh DB; Patel DN; Yeagley M; Hsiang M; Blanck G
Genes Immun; 2023 Apr; 24(2):92-98. PubMed ID: 36805542
[TBL] [Abstract][Full Text] [Related]
5. Immunogenetic Profiles and Associations of Breast, Cervical, Ovarian, and Uterine Cancers.
James LM; Georgopoulos AP
Cancer Inform; 2023; 22():11769351221148588. PubMed ID: 36684415
[TBL] [Abstract][Full Text] [Related]
6. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC.
Liu J; Geng R; Ni S; Cai L; Yang S; Shao F; Bai J
Mol Ther Nucleic Acids; 2022 Mar; 27():1036-1055. PubMed ID: 35228898
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic control of Tcrb gene rearrangement.
Spicuglia S; Pekowska A; Zacarias-Cabeza J; Ferrier P
Semin Immunol; 2010 Dec; 22(6):330-6. PubMed ID: 20829066
[TBL] [Abstract][Full Text] [Related]
8. On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments.
Toor AA; Toor AA; Rahmani M; Manjili MH
J R Soc Interface; 2016 Jan; 13(114):20150911. PubMed ID: 26763333
[TBL] [Abstract][Full Text] [Related]
9. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates.
Clark KR; Tong WL; Callahan BM; Yavorski JM; Tu YN; Blanck G
Int J Immunogenet; 2019 Feb; 46(1):31-37. PubMed ID: 30474304
[TBL] [Abstract][Full Text] [Related]
10. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates.
Arndt MF; Koohestani DM; Chobrutskiy BI; Mihyu MM; Diaz M; Gozlan EC; Yeagley M; Zaman S; Roca AM; Blanck G
Hum Immunol; 2020 Dec; 81(12):692-696. PubMed ID: 32950267
[TBL] [Abstract][Full Text] [Related]
11. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates.
Tong WL; Callahan BM; Tu YN; Zaman S; Chobrutskiy BI; Blanck G
Breast Cancer Res Treat; 2019 Jan; 173(1):167-177. PubMed ID: 30229447
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates.
Roca AM; Chobrutskiy BI; Callahan BM; Blanck G
Hum Immunol; 2019 Apr; 80(4):237-242. PubMed ID: 30684568
[TBL] [Abstract][Full Text] [Related]
13. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade.
Chobrutskiy BI; Zaman S; Tong WL; Diviney A; Blanck G
J Neurooncol; 2018 Dec; 140(3):697-704. PubMed ID: 30382482
[TBL] [Abstract][Full Text] [Related]
14. T-cell receptor-β V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns.
Callahan BM; Yavorski JM; Tu YN; Tong WL; Kinskey JC; Clark KR; Fawcett TJ; Blanck G
Cancer Immunol Immunother; 2018 Jun; 67(6):885-892. PubMed ID: 29508024
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
